132 related articles for article (PubMed ID: 38518683)
1. Ineffectiveness of colistin monotherapy in treating carbapenem-resistant Acinetobacter baumannii Pneumonia: A retrospective single-center cohort study.
Jeon CH; Kim SH; Kim HT; Park KJ; Wi YM
J Infect Public Health; 2024 May; 17(5):774-779. PubMed ID: 38518683
[TBL] [Abstract][Full Text] [Related]
2. Antibiotic strategies and clinical outcomes in critically ill patients with pneumonia caused by carbapenem-resistant Acinetobacter baumannii.
Liang CA; Lin YC; Lu PL; Chen HC; Chang HL; Sheu CC
Clin Microbiol Infect; 2018 Aug; 24(8):908.e1-908.e7. PubMed ID: 29108947
[TBL] [Abstract][Full Text] [Related]
3. The effectiveness and nephrotoxicity of loading dose colistin combined with or without meropenem for the treatment of carbapenem-resistant A. baumannii.
Katip W; Uitrakul S; Oberdorfer P
Int J Infect Dis; 2020 Aug; 97():391-395. PubMed ID: 32502665
[TBL] [Abstract][Full Text] [Related]
4. Risk factors and mortality of patients with nosocomial carbapenem-resistant Acinetobacter baumannii pneumonia.
Zheng YL; Wan YF; Zhou LY; Ye ML; Liu S; Xu CQ; He YQ; Chen JH
Am J Infect Control; 2013 Jul; 41(7):e59-63. PubMed ID: 23523521
[TBL] [Abstract][Full Text] [Related]
5. What is the optimal antibiotic treatment strategy for carbapenem-resistant Acinetobacter baumannii (CRAB)? A multicentre study in Korea.
Seok H; Choi WS; Lee S; Moon C; Park DW; Song JY; Cheong HJ; Kim J; Kim JY; Park MN; Kim YR; Lee HJ; Kim B; Pai H; Jo YM; Kim JH; Sohn JW
J Glob Antimicrob Resist; 2021 Mar; 24():429-439. PubMed ID: 33571708
[TBL] [Abstract][Full Text] [Related]
6. The prevalence, presentation and outcome of colistin susceptible-only Acinetobacter Baumannii-associated pneumonia in intensive care unit: a multicenter observational study.
Wang SH; Yang KY; Sheu CC; Lin YC; Chan MC; Feng JY; Chen CM; Chen CY; Zheng ZR; Chou YC; Peng CK
Sci Rep; 2023 Jan; 13(1):140. PubMed ID: 36599842
[TBL] [Abstract][Full Text] [Related]
7. Insights into the epidemiology, risk factors, and clinical outcomes of carbapenem-resistant
Zhang Y; Xu G; Miao F; Huang W; Wang H; Wang X
Front Public Health; 2023; 11():1282413. PubMed ID: 38098829
[TBL] [Abstract][Full Text] [Related]
8. Clinical effectiveness of cefiderocol for the treatment of bloodstream infections due to carbapenem-resistant Acinetobacter baumannii during the COVID-19 era: a single center, observational study.
Oliva A; Liguori L; Covino S; Petrucci F; Cogliati-Dezza F; Curtolo A; Savelloni G; Comi M; Sacco F; Ceccarelli G; Viscido A; Alessandri F; Raponi G; Pugliese F; Mastroianni CM; Venditti M
Eur J Clin Microbiol Infect Dis; 2024 Jun; 43(6):1149-1160. PubMed ID: 38634975
[TBL] [Abstract][Full Text] [Related]
9. Treatment Outcomes of Colistin- and Carbapenem-resistant Acinetobacter baumannii Infections: An Exploratory Subgroup Analysis of a Randomized Clinical Trial.
Dickstein Y; Lellouche J; Ben Dalak Amar M; Schwartz D; Nutman A; Daitch V; Yahav D; Leibovici L; Skiada A; Antoniadou A; Daikos GL; Andini R; Zampino R; Durante-Mangoni E; Mouton JW; Friberg LE; Dishon Benattar Y; Bitterman R; Neuberger A; Carmeli Y; Paul M;
Clin Infect Dis; 2019 Aug; 69(5):769-776. PubMed ID: 30462182
[TBL] [Abstract][Full Text] [Related]
10. Current treatment options for pneumonia caused by carbapenem-resistant Acinetobacter baumannii.
Franzone JP; Mackow NA; van Duin D
Curr Opin Infect Dis; 2024 Apr; 37(2):137-143. PubMed ID: 38179988
[TBL] [Abstract][Full Text] [Related]
11. Prospective observational study of the impact of plasma colistin levels in patients with carbapenem-resistant Acinetobacter baumannii pneumonia.
Jeong YJ; Gu N; Kwack WG; Kang Y; Park SY; Yoon YS
J Glob Antimicrob Resist; 2021 Dec; 27():315-323. PubMed ID: 34775134
[TBL] [Abstract][Full Text] [Related]
12. Trimethoprim-sulfamethoxazole vs. colistin or ampicillin-sulbactam for the treatment of carbapenem-resistant Acinetobacter baumannii: A retrospective matched cohort study.
Raz-Pasteur A; Liron Y; Amir-Ronen R; Abdelgani S; Ohanyan A; Geffen Y; Paul M
J Glob Antimicrob Resist; 2019 Jun; 17():168-172. PubMed ID: 30557685
[TBL] [Abstract][Full Text] [Related]
13. Cefiderocol- Compared to Colistin-Based Regimens for the Treatment of Severe Infections Caused by Carbapenem-Resistant Acinetobacter baumannii.
Falcone M; Tiseo G; Leonildi A; Della Sala L; Vecchione A; Barnini S; Farcomeni A; Menichetti F
Antimicrob Agents Chemother; 2022 May; 66(5):e0214221. PubMed ID: 35311522
[TBL] [Abstract][Full Text] [Related]
14. Phenotypic and molecular characterization of Acinetobacter baumannii isolates causing lower respiratory infections among ICU patients.
Jain M; Sharma A; Sen MK; Rani V; Gaind R; Suri JC
Microb Pathog; 2019 Mar; 128():75-81. PubMed ID: 30562602
[TBL] [Abstract][Full Text] [Related]
15. Colistin Plus Carbapenem versus Colistin Monotherapy in the Treatment of Carbapenem-Resistant
Shi H; Lee JS; Park SY; Ko Y; Eom JS
Infect Drug Resist; 2019; 12():3925-3934. PubMed ID: 31920347
[TBL] [Abstract][Full Text] [Related]
16.
Soudeiha MAH; Dahdouh EA; Azar E; Sarkis DK; Daoud Z
Front Cell Infect Microbiol; 2017; 7():209. PubMed ID: 28596943
[TBL] [Abstract][Full Text] [Related]
17. Colistin-based treatment for extensively drug-resistant Acinetobacter baumannii pneumonia.
Khawcharoenporn T; Pruetpongpun N; Tiamsak P; Rutchanawech S; Mundy LM; Apisarnthanarak A
Int J Antimicrob Agents; 2014 Apr; 43(4):378-82. PubMed ID: 24613422
[TBL] [Abstract][Full Text] [Related]
18. Risk factors of mortality in patients with carbapenem-resistant Acinetobacter baumannii bacteremia.
Liu CP; Shih SC; Wang NY; Wu AY; Sun FJ; Chow SF; Chen TL; Yan TR
J Microbiol Immunol Infect; 2016 Dec; 49(6):934-940. PubMed ID: 25553994
[TBL] [Abstract][Full Text] [Related]
19. Colistin treatment in carbapenem-resistant Acinetobacter baumannii pneumonia patients: Incidence of nephrotoxicity and outcomes.
Kwon KH; Oh JY; Yoon YS; Jeong YJ; Kim KS; Shin SJ; Chung JW; Huh HJ; Chae SL; Park SY
Int J Antimicrob Agents; 2015 Jun; 45(6):605-9. PubMed ID: 25772644
[TBL] [Abstract][Full Text] [Related]
20. [Risk factors and resistance patterns of invasive
Ge YL; Shan QW; Qiu Y; Zhou SP; Cheng YB; Wang F; Yang JW; Wan CM; Zhu Y; Xu Y; Chen MX; Lin DJ; Zhu CH; Zeng M
Zhonghua Er Ke Za Zhi; 2022 Aug; 60(8):762-768. PubMed ID: 35922185
[No Abstract] [Full Text] [Related]
[Next] [New Search]
